Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Reduces salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and…. ANDA 210927, held by Prinston. Glycopyrrolate.
As of Nov 15, 2026, ANDA 210927 (Glycopyrrolate), held by Prinston, was first approved by FDA on Oct 31, 2018, with 0 approved supplements and 0 published complete response letters.
First approved: Oct 31, 2018
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Glycopyrrolate injection is an anticholinergic indicated: in anesthesia (adult and pediatric patients)
for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation.
intraoperatively to counteract surgically or drug-induced or vagal reflex- associated arrhythmias.
for protection against peripheral muscarinic effects of cholinergic agents. in peptic ulcer (adults)
To reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer when rapid anticholinergic effect is desired or oral medication is not tolerated.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
